Eli Lilly launches compassionate‑use program for experimental obesity drug Retatrutide in the United States

Eli Lilly announced a compassionate‑use (expanded‑access) program that will allow a limited group of severely obese patients in the United States to receive Retatrutide before the drug receives formal FDA approval. Retatrutide is an experimental weekly injection that simultaneously targets the GLP‑1, GIP and glucagon receptors and is currently in Phase 3 clinical trials for obesity and related conditions such as cardiovascular disease, sleep‑apnea, metabolic liver disease, chronic kidney disease, knee osteoarthritis and type‑2 diabetes.

Eligibility is restricted to adults 18 years or older who have refractory obesity after maximal standard therapy, present at least two serious weight‑related complications, and are not eligible for ongoing clinical trials. The company warned that products sold outside the trial may contain unknown ingredients or incorrect doses, posing health risks. The program is limited to the United States and does not constitute general market availability.